31 Jul Purchase your copy of BS EN as a PDF download or hard copy directly from the official BSI Shop. All BSI British Standards. 16 Aug Denna standard ersätter SS-EN , utgåva 1. The European Standard EN has the status of a Swedish Standard. AND DIN EN ,. The Certification Body for Structural Metallic Products of TÜV NORD Systems GmbH & Co. KG hereby confirms in accordance with.
You can change these settings at any time, by invoking our Data protection declaration. Log out after your purchase. En 15048-1 activating this functionality, your login data customer number and partner number is saved as a so called En 15048-1 on rn local file system. You can therefore decide not to accept certain types of Cookies.
Thread type x nominal diameter d 1 M12 Length l 1 mm Head height k 1 7.
Nuts and bolts shall be 150048-1 and supplied in the original and unopened box. Declaration of performance LV. Requirements EN contains regulations governing products used for the design, calculation en 15048-1 manufacture of non-preloaded bolt connections for steel structures. If you use non-certified nuts and bolts for steel structures after 1 July you will be violating European law en 15048-1 all the consequences that entails!
EN describes the bolt connectors in which reference is eb to standard EN en 15048-1 non-preloaded structural bolts and EN for preloaded bolts.
En 15048-1 of en 15048-1 NL. Forside Nettbutikk Produktkatalogen Produktpresentasjon. NOTE 2 High-strength structural bolting assemblies for preloading which meet the requirements of EN —1 are not within the scope of this European Standard but they are also suitable for use in non-preloaded structural bolting.
You can register online in a few simple steps. Products 155048-1 Site contents.
For en 15048-1 reason Stafa keeps a complete range of structural bolts which conform to EN More about EN you can find here. Declaration of performance DE. Stafa offers you all the expertise in the field of this en 15048-1 legislation so that you are assured of the right products. No order templates available.
Part 150481- sets out the general requirements and part 2 the suitability test.
Declaration en 15048-1 performance ET. To log in with your mobile phone number please enter your mobile phone number, verified during the registration process. In generally we suggest: Declaration of performance RU. Declaration of performance PT.
It will be displayed on the first page, in the top en 15048-1 hand corner.
Click on "Register now". The password must be at least 8 characters long en 15048-1 1048-1 composed of numbers and letters, with at least 4 different characters. You can create a new order template here. Declaration of performance PL. It applies to bolts the term used when bolts partially threaded, screws, studs and stud-bolts are considered all together and nuts made en 15048-1 carbon steel, alloy steel, stainless steel or aluminium or aluminium alloy with 15408-1 following property classes: NOTE 3 Bolts and nuts made of aluminium or aluminium alloys are not designed to be used in steel structures, see EN —2.
Railway rail fasteners are not covered by this European Standard. Declaration of performance ES.


CHELSEA — Most of the sounds on this stretch of West 20th Street are not surprising. Taxis zoom, buses whoosh and passers-by chatter on cell phones. But, in the lobby of a nondescript office building, you can hear something more unusual for this neighborhood — gunshots.
The basement is the site of Westside Rifle and Pistol Range, the only shooting range in Manhattan. Owner Darren Leung says that, while he serves licensed and experienced handgun owners, demand for his more introductory riflery classes is soaring.
In February the range, close to the intersection with Fifth Avenue, offered a coupon through the online discount service at Yelp.com.
"They offered 2,000 hits and it was sold out in one night," says Leung. "That tells you exactly what's going on with this."
Leung credited a desire for personal protection as a factor in the increased interest in shooting. But he found a surprising alternative reason for the people coming through the door for target-shooting classes — date night.
"A lot of people have figured out that on a date it's pretty cool to come down and shoot a couple rounds, then go out to dinner," Leung said. He added that New Yorkers who think guns are taboo might get an extra thrill from the experience.
On a recent Thursday afternoon, sweethearts Ian Brodman and Nirmala Rampersad came in for their first lesson.
By the end, Brodman, 41, was already asking how he could buy his own firearm. Rampersad, 29, was not yet sold. She admitted that she had been nervous at first: "I was shaking when I held the gun."
By the end of the session, though, she said she was glad that she'd joined millions of other Americans by giving it a shot.
Across the country, sport shooting is more popular than ever with a record 34.4 million people participating, according to the National Shooting Sports Foundation.
People are buying more rifle gear too, even as sales of other sporting goods decrease. In 2009, the National Sporting Goods Association reported a 14 percent increase in the sales of shooting equipment from the year before, and a 10 percent hike in participation nationwide over the last decade.
Only 11 percent of people in the Northeast have shot for sport in the last year, making it the least saturated region. The highest is the Midwest, at 18 percent.
But Westside is proof that the national vogue for shooting sports has penetrated New York City.
While handgun permits can take months to process and cost upwards of $400, anyone with $65 and a clean record can sign up for Westside's rifle workshops. Westside trains interested marksmen and women on old-fashioned semiautomatic .22-caliber rifles.


Business Experts and Therapists Sue Haswell and Cathy Towers deliver two days' Business Therapy. Read more about them on https://www.biztherapy.co.uk/about-us.
A 2-day workshop for people who are "stuck" in their businesses and for Laughter Yoga Professionals there is a special price so get in touch.
you are fed up and bored with your business.
you don't get enough from your business – money/fun/enjoyment/learning.
life has moved on and has different demands on you – family, health, home, relationships.
other businesses are looking like success, but yours isn't.
the industry has moved on – but you haven't.
you have faced some challenge and haven't recovered fully yet.
you have lost your confidence.
you have lost you mojo.
you no longer want your mojo – but feel you have to continue.
the business is part of your identity, but you want to change it and don't know how.
you want to grow/de-grow/move/change/sell or otherwise make a fundamental change.
you just feel stuck for some inexplicable reason.
your business is not doing you any favours and every single day continues to drag you down.
The Business Therapy workshop helps you take a whole bright new look at the business! It's not prescriptive, and we aren't attached to any outcomes.


text:
Forces of Geek
we like pop culture.
About FOG!
Columns/Features
Clothing/Misc.
Merchandise / Collectibles
Movies/Blu-ray/DVD
Art/Collectibles
Gadgets/Tech
East Dragon, West Dragon: SCOTT C. So Happy!
May 3, 2012 by Stefan Blitz
When I was a wee tacker growing up in Melbourne, my dad picked up this second hand tome called Myths and Legends, published by Paul Hamlyn way back in 1959.
The illustrators were the insanely cool Alice and Martin Provensen, and it turns out that Martin was also the originator of the first Tony the Tiger character for Kellogg's – an iconographic '50s feline that decorates my fave coffee mug these days.
About five years ago, I started writing for an American magazine called Geek Monthly and, a few issues in, they showcased a relatively new artist/illustrator named Scott Campbell, alias Scott C.
To me, his images were akin to the Provensens, channelled via Blackadder writers Richard Curtis and Ben Elton, and then stretched to the point of surreal hilarity by Dr. Seuss.
I was busy hacking together a novel at the time (Tobacco-Stained Mountain Goat) and my publishers at Another Sky Press asked if I'd decided yet who I'd like to get to do the cover artwork.
That was now a cinch – all I had to do was track down and ask Campbell if he'd be interested. After some crap detective work, I did so, and he agreed in an instant, very few questions asked, and turned out a way cool couple of goats.
I always wanted to interview Scott in order to find out the buried treasure beneath his easy-going artist facade – and I finally did so this last month, on the back of his fantastic new children's tome East Dragon, West Dragon, which my six-year-old daughter Cocoa loves as much as me, by the way.
So, first up, how did Scott get started doing art, remain inspired, and stumble across his own unique style?
"I think it's a combination of all the comic books and children's books I grew up with," he appraises, "Coupled with all the movies and cartoons I've enjoyed through the years–and the people I experience around me everyday. Right now, I'm most inspired by Charlie Harper, an illustrator big since the '50s. I love his colors and the awesome shapes he finds in things. Same goes for Jon Klassen and the Provensens. Jon is a contemporary illustrator who designed an amazing water conservation commercial, among other thing, and he's also very good with shapes and colors and textures. The Provensens illustrated kids' books in the '50s and have this sensibility. But I also like artists like Banksy a whole lot. I saw his pet store he did here in New York, and it inspired me more than anything I've seen in a long time. I've never seen anything like it – super clever, and made me very interested in how people participate in shows when they come to see them."
Tell us a bit about the character of East Dragon in your new book East Dragon, West Dragon – do you see him as pan-Asian, or a tad more Japanese?
"Definitely erring more on the Japanese tip because I am just so obsessed with Japan. This was a big discussion my editor and I had, Japanese versus Chinese. We didn't want to combine the styles and hopefully that is all right. I have researched Japanese architecture and culture for many paintings I've done in the past, so I wanted to be accurate and respectful, but obviously not super realistic with everything. I put much more modern day stuff into the medieval scenes, though… like TVs and an Atari, and what not."
What things particularly influenced the way in which you developed the 'look' of the character, and how much input did writer Robyn Eversole have regarding the visuals?
"Robyn actually wasn't involved in the illustration process too much. We sent her the drawings and she said, 'Yeah, cool!' It was mostly Namrata [the editor] and Sonia [the art director] who gave me feedback. I sketched some ideas and they would critique them and give me sweet feedback. We settled on things together."
East Dragon seems more culturally proactive than West Dragon, doing calligraphy and what not; heck, he even wears a kimono. Do you think he really is?
"Yeah, I think East Dragon and his brothers and sisters are very culturally proactive and respectful – that must be why they get along so well with the emperor and the other civilians. West Dragon is obviously in his own zone and doesn't care as much, and the knights and kings are always sort of bothering him. They aren't a happy family as much as in the East. That is how it seemed in Robyn's story and I wanted to portray that a bit in how they lived."
I could be wrong, but you seem to dig working with Australian writers. What's the attraction?
[Laughter] "It is true. I just find myself hanging out with Australians in the strangest places. Those guys are always strolling about town."
Your back catalogue is littered with images of zany ninja, kaiju-style monsters in onsens, and other Japanese-influenced asides. What's the attraction of Japan in general, and in particular in visual terms?
"I've been obsessed with Japan ever since I visited with my two friends in the year 2000. My friend's father lived in Kumamoto, in the south [in Kyushu], and he took us all over Japan to visit his old bros. It was an unbelievable trip because each of his friends had a completely different personality. There was the one old bro who lived in the mountains with his family creating ceramics in a huge kiln that he built. There was the businessman who lived in Kyoto, the super sporty fellow who took us waterskiing on a lake near Osaka, the wild dude with ferrets running all over the place in Tokyo. It was an amazing trip. A few years later, I went back with about twenty friends to do an art show in Tokyo with an art collective that I went to art school with. But I really just fell in love with everything there, from the vending machines and cartoon characters on everything, to how pleasant everyone was to us. And how clean it was! I could go on about specific things that I liked, but it would be a long list. My art became super-inspired by what I saw on that first trip – I came back with lots of books and objects!"
Who are your favorite Japanese filmmakers, anime directors, manga stars, musicians, visual artists, etc?
"Well, I love 'Beat' Takeshi and Akira Kurosawa. I mean, I guess 'Beat' Takeshi goes by something else with his films? [He does – Takeshi Kitano]. I grew up loving Robotech and Ultraman – big, big influences on me. [Hayao] Miyazaki and [Katsuhiro] Otomo for animated films. [Shigeru] Miyamoto for video games. So many people! The creativity is so insane and super-inspiring to me… in everything. There is a reason why American television always looks to recreate Japanese game shows like Iron Chef and Silent Library. I am so happy that Japan exists. So happy!"
Sneak Peak: SAVAGE DRAGON #173
In stores this week from Image Comics and Erik Larsen! It's Malcolm Dragon vs. Mr.…
Filed Under: General, Interviews Tagged: Art/Design, Asian Pop Culture, Books/Literature, Interview, Written by Andrez Bergen
New Scooby-Doo Playsets from PLAYMOBIL! January 17, 2020
Catwoman 80th Anniversary 100-Page Super Spectacular #1 Arrives April 15, 2020 January 17, 2020
Podcasts Celebrating Television's Past January 17, 2020
'The Joker 80th Anniversary 100-Page Super Spectacular #1' Celebrates Eight Decades of Chaos, Mischief, and Mayhem January 17, 2020
'Free S**t' by Charles Burns (review) January 17, 2020
INTERVIEWS YOU MIGHT HAVE MISSED
FOG! Chats With SUPER HUMAN RESOURCES Creator KEN MARCUS!
FOG! Chats With 'Stumptown' Artist Justin Greenwood
JANIS JOPLIN'S Final Interview Realized As An Animation
FOG! Chats With Writer JUSTIN JORDAN About His Sleepless Creation, JOHN FLOOD!
FOG! Chats With PACIFIC RIM Writer and World Builder TRAVIS BEACHAM
Connect with FOG!
DISCLAIMER: Forces of Geek is protected from liability under the DMCA (Digital Millenium Copyright Act) and "Safe Harbor" provisions. All posts are submitted by volunteer contributors who have agreed to our Code of Conduct. FOG! will disable users who knowingly commit plagiarism, piracy, trademark or copyright infringement. Please contact us for expeditious removal of copyrighted/trademarked content.
Copyright © 2020 — Forces of Geek • All rights reserved.

redpajama_set_name: RedPajamaCommonCrawl


text:
25 Interesting Facts About World War II
Learn about 25 interesting and fascinating facts about the Second World War that you may not know.
10 Interesting Facts about Martin Luther King Jr.
Learn 10 interesting and fascinating facts about Dr Martin Luther King Jr, a key figure in the American Civil Rights Movement.
Learn 10 interesting and fascinating facts about Samuel Langhorne Clemens, a legendary writer better known as his pen name Mark Twain.
10 Interesting Facts About John F. Kennedy
Learn 10 interesting and fascinating facts about John F. Kennedy who served as the 35th President of the United States.
10 Interesting Facts About Amelia Earhart
Learn 10 interesting and fascinating facts about Amelia Earhart who was best known as an author and pioneer of aviation.
Fascinating and interesting facts about Thomas Jefferson, who served as the 3rd President of the United States and was a Founding Father.
10 Interesting Facts About Tsar Nicholas II
Learn about 10 Tsar Nicholas II facts that you may not know. Find out more about Nicholas who was the last emperor of the Russian Empire.
10 Interesting Facts About Theodore Roosevelt
Theodore Roosevelt's history has been thoroughly documented; but here are 10 facts about Theodore Roosevelt you may not have known.
10 Interesting Facts About Al Capone
Al Capone had his criminal life thoroughly documented by many law enforcement organizations, but you may not have known these 10 facts about him.
10 Interesting Facts About Joe Biden
Many people already know about the political history of Joe Biden, but not many people may know these 10 facts about his personal life.
9 Interesting Facts About Thomas Edison
Find out 9 fascinating facts about Thomas Edison, one of the United States' most famous inventors and businessmen.
10 Interesting Facts About Leonardo da Vinci
Read and Learn 10 fascinating facts about Italian polymath Leonardo da Vinci, one of the greatest minds to ever exist.
Divorced, Beheaded, Died: Henry VIII's Six Wives
Who was the First President to be Photographed?
The Biography of American Photographer Gordon Parks
Tudor Monarchs History Quiz
Cold War Quiz
Ancient Greece History Quiz
First Ladies of the United States of America Quiz
The Battle Over the Body of Jim Thorpe
Yuri Gagarin: The First Man In Space
The Rise and Fall of the Steam Car
How did surgeon Robert Liston accidentally kill three people in one day?
See a colorized photo of Charles Darwin, circa 1874


text:
namespace Google.Cloud.DataQnA.V1Alpha.Snippets
{
    // [START dataqna_v1alpha_generated_QuestionService_GetQuestion_sync_flattened]
    using Google.Cloud.DataQnA.V1Alpha;

    public sealed partial class GeneratedQuestionServiceClientSnippets
    {
        /// <summary>Snippet for GetQuestion</summary>
        /// <remarks>
        /// This snippet has been automatically generated and should be regarded as a code template only.
        /// It will require modifications to work:
        /// - It may require correct/in-range values for request initialization.
        /// - It may require specifying regional endpoints when creating the service client as shown in
        ///   https://cloud.google.com/dotnet/docs/reference/help/client-configuration#endpoint.
        /// </remarks>
        public void GetQuestion()
        {
            // Create client
            QuestionServiceClient questionServiceClient = QuestionServiceClient.Create();
            // Initialize request argument(s)
            string name = "projects/[PROJECT]/locations/[LOCATION]/questions/[QUESTION]";
            // Make the request
            Question response = questionServiceClient.GetQuestion(name);
        }
    }
    // [END dataqna_v1alpha_generated_QuestionService_GetQuestion_sync_flattened]
}

redpajama_set_name: RedPajamaGithub


Gold and silver prices are lower a day after the Federal Reserve made further cuts to its economic stimulus program.
The actively traded April contract for gold fell $19.70, or 1.6 percent, to $1,242.50 an ounce Thursday. Silver for March delivery fell 42.6 cents, or 2.2 percent, to $19.126 an ounce.
Gold and silver lost more of their appeal as havens for investors after the Fed announced more reductions in its bond-buying program late Wednesday.
Traders had bid up the prices of both metals expecting that the Fed's program would weaken the dollar and cause inflation. That never happened, and now that the program is winding down, the threat is diminishing even further.
Natural gas prices plunged 8 percent after soaring the day before.


text:
Gettin' Air
Innovation Labcast
About the Innovation Labcast
Teach With Care
The New Professor
Better Together – A #SquadGoalsNetwork Reflection from Angela Gunder
by Angela Gunder
A reflection by Angela Gunder on the power of personal learning networks.
ACCESS – Does regular access to other individuals from other institutions and institutional perspectives challenge your definition of access and what it means? If so, how?
We spend a lot of time within academia mitigating feelings of "lone wolfism" – we're stuck in our challenges on our own and have to go it alone in figuring out what to do. Worse than that, we're completely dependent on the resources we're able to source ourselves in order to implement the solutions that our institutions desperately need. How can we increase our connectedness and our effectiveness in better serving our students?
Key to conquering the insurmountable challenge of accomplishing more with less is extending the reach of one's network with an interconnected group of trusted experts. By breaking down the silos that separate us at our individual institutions, we can crowdsource solutions, collaboratively test effective practices, and learn from the failures and iterations of our colleagues. I've seen this in action no stronger than in my connections to the individuals I've had the honor and pleasure of working with after meeting at conferences, and chiefly my collaborations with the Online Learning Consortium. The folks that I've met, first an attendee and later as a committee member, have been instrumental in the formation of my trusted network of colleagues. Without them I would not have the ability to effectively serve the members of The University of Arizona community I've been entrusted with supporting, chiefly the students of UA Online. Beyond the connection working to of tear down the walls of proprietary knowledge within institutions, my PLN helps me to balance all of the responsibilities on my plate. When I came to The University of Arizona in 2014, I quickly earned a seat at the table in the build out of the team entrusted with producing all of the fully-online degree programs for UA Online. I wore (and continue to wear) many hats, to include manager, mentor, designer, educator and student (as I write this, I am, along with many others in our squad, pursuing a Ph.D.). My network supported (and continues to support me) in all of these endeavors, clearing the pathway for me to expand access to a rigorous, experiential online education for our students. I am humbled by their generosity and will do anything to pay it forward and return the favor by supporting them in all of their efforts.
The Squad Goals Network website serves as an artifact of this expansion of access – like a star map, the site attempts to chart the reach of not only the network that I sit within (a constellation), but of all of the interconnected networks (think galaxies) that allow me to be successful within the field. And the site can only dream of capturing the sheer, unmitigated joy that we all experience when working together. Our passion is amplified, and this is spun out into rich collaborations, open research, and dance moves. So many dance moves.
FACULTY SATISFACTION – How has your participation in the PLN benefitted faculty and colleagues at your home institution?
There is a synergistic relationship between the support that I have received from my network and the work that I do at my institution in supporting my faculty and colleagues. Conversely, the work that I do at The University of Arizona allows me to bring back to my network new methods, techniques, and tangible resources that aid them in their efforts. As the network expands, so does the depth of the collection of resources, thereby ensuring that my faculty are robustly supported in their work within and beyond the classroom.
Concrete examples of this in action can be seen with the way that I have been able to take initiatives that were incubated at the conferences I've attended and planned, and bring them back to The University of Arizona to remix them with my colleagues. The chief example of this would be my serving as a chef in the Technology Test Kitchen (TTK) at OLC Accelerate – the exploratory makerspace became a trusted hub for working out challenges that my faculty and colleagues faced. I could crowdsource approaches to issues with scaling access to education, and bring back new technology that had been tested and proven effective. Moreover, the collaborations that began in the space extended out beyond the conference itself. For instance, after working in the TTK for two of the OLC conferences, Ben Scragg, Dave Goodrich and I were tasked with building out a new space called the Innovation Lab. Created as a design thinking "collaboratorium," the conversations that the entire team had around designing and facilitating the lab quickly evolved into a weekly podcast that kept the design efforts alive throughout the year. It was in these recordings that we forged deeper connections with the members of the network, interviewing our colleagues and workshopping our ideas for new initiatives and efforts. For me personally, this was also the space in which I truly learned to podcast, and I've been able to share that knowledge with faculty who have wanted to add this modality to their toolkit for offering course content to their online students.
The TTK and Innovation Lab also served as the catalysts for the ways in which my office delivers professional development both within and beyond our institution. A TTK chef and my colleague at The University of Arizona, Michael Griffith shared an idea at a debriefing meeting to bring the TTK home to individual institutions with a "tech crawl." Faculty and staff would travel from station to station and learn more about the tools and innovative practices that their colleagues were enacting that were "best-kept secrets" within their institution. We created our first UA Tech Crawl the evening before we hosted an OLC Collaborate event, allowing our faculty and staff to network with participants arriving early for the one-day conference the next day. The event was such a great success in bringing folks together over shared effective practices, we've since held several for different colleges and campuses within the UA and for our neighbors at Pima Community College. The format is lightweight (each station requires a laptop and that's it!) and provides participants with the opportunity to leave with anywhere from 8-10 brand new, actionable approaches that they can implement in their teaching and learning. An added benefit is that the format affords presenters a way to connect and bond over shared practices as well, serving as a team building exercise within and across offices.
Lastly, born from the OLC Innovate conference, the Solution Design Summit (SDS) was an initiative that allowed interdisciplinary, institutional teams to come together to solve challenges brought in directly from their schools live at the conference. While initially designed as a competition, the format allowed for the creation of sharable effective practices of immediate impact. After participating in the SDS as a UA team, Matt Romanoski and Janet Smith decided to take the format and remix it to allow for monthly team design challenges. Team members would crowdsource and upvote challenges to tackle, and then another member of the team, Katy Holt, would facilitate a design thinking exercise to generate approaches to solving the issue. At the end of the session, participants would choose components of the proposed solution to work on for a set timeline, and report out on the progress at later meetings. This remixed SDS format worked so well that in the 2018 Innovation Lab, members of the UA Online team contributed their findings and the event format to the planning of the SDS at the conference. This was one of many examples of how participation in the PLN effectively created a push and pull of information to and from the conference, creating an organic system by which faculty and colleagues were better supported.
LEARNING EFFECTIVENESS – When you reflect on your work, how has meeting and learning from individuals from other institutions and institutional perspectives helped you to clarify or re-define what it means for learning to be effective?
A huge part of our work in the field of online learning is situated within research – beyond the need for many to publish as part of their job duties, everyone within our field is called to improve practice with data-driven decision making. Expanding access to research is critical to not only innovation, but also to ensuring that our daily practices are truly in service to students and their learning. For many practitioners, there seems to be divide between their work and the work of the stereotypical researcher, when in fact, we are all in the business of sharing practice. At its heart, research is as simple as sharing evidence of the effectiveness of a practice (or lack thereof) in the hopes of helping others in the field. The PLN has served as way to not only demystify the practice of research, but as a means of expanding access to new ideas that have been rigorously tested, iterated and remixed. Our collaborations on articles, book chapters, conference proceedings, white papers, and even academic blog posts have all allowed us to determine what it means to measure learning effectiveness in our unique contexts, and more broadly across online education as a whole. My favorite collaboration to come out of the network has been our research on the concept of applying Joseph Campbell's monomyth to the online course design process. What started as a "What if…" question posed by my UA colleague, Cathy Russell, has now morphed into a framework and a bevy of resources that have been generated by a team of epic win (which includes Jess Knott, John Stewart and Keegan Long-Wheeler in addition to Cathy and myself), each of whom has left their indelible mark on the shared work of reimagining the epic heroes of online education.
These co-writing and publishing efforts are underscored by cross-institutional visits and collaborations, many of which occur both online and in-person and include the connecting of entire teams. The conversations highlight institution-specific variations in ubiquitous challenges as examined at the regional, national and international levels. They also serve as a way to discover new avenues and topics for critical research, illuminating questions that will help to generate new knowledge to better inform our practice. In the short time that I have been involved with my squad, I've had the pleasure of collaborating with dozens of institutions, many of which I've been able to visit in person. I've had the honor of connecting my team to other individuals seeking answers to critical issues that we've been able to work on (and in many cases, that we've tackled). Best of all, I have learned firsthand of the depth of support that one benefits from in having a network of dedicated to the sharing of knowledge, collaborative research, and open iteration of ideas.
SCALE – Is the PLN scalable and/or replicable by others at other institutions/organizations? If so, how? What challenges do you encounter?
It's easiest to discuss scale when talking about this effective practice in that, at its heart, it's built around the concept of expanding the reach and access of our efforts. We intrinsically know that we can't meet the needs of our institutions – chiefly increasing access to education – without scaling our access to resources. As budgets are lean and in some places personnel limited, we must find other ways to be innovative in service to students. The creation of a rich and robust PLN is, by definition, scaling resources to support students. Plain and simple.
STUDENT SATISFACTION – Do you feel that your involvement and/or collaboration with the PLN has helped you create better student experiences at at your institution?
In a position dedicated to the support of students, I simply could not do my job if I did not have a robust network of colleagues to lean on for assistance. Beyond expanding my access to research and support, joining efforts affords the network the ability to test at scale without losing the freedom to fail. It also extends the impact of the research that is generated. Innovation takes risk, to be sure, but it also requires discipline and tenacity. Working within a trusted group of networked colleagues mitigates risk, but also answers that bigger question of how we persist when we find ourselves struggling with the challenges in front of us. Knowing that I have the support of my colleagues helps me to focus on and enact the decisions that are best for my students as opposed to simply implementing the solutions that are the easiest. I lean on my colleagues to help me create meaningful and measurable initiatives that directly impact student engagement, retention and satisfaction. Best of all, my work is elevated by our collective efforts to bring student voices to the table and champion them the best ways that we can only do if we work together.
About the Author / Angela Gunder
angela.gunder@gmail.com
When she's not helping maintain this site as one of the authors of the Squad Goals Network, Angela Gunder serves as the Director of Instructional Design & Curriculum Development for the Office of Digital Learning at The University of Arizona.
Home on the Range with Ranger Davie – Innovation Labcast Episode #004
This Shouldn't Be Here
Caitlin Kerrigan, Coordinator, Faculty Programs, Campus Life
Meet the Editors – Kate Sonka
What would you say… you do here?
#SquadGoalsNetwork Salons
A constellation of networked educators, incubating new ideas and fostering connections, all in an effort to expand equity and access within higher education
Practicing Useful Self-Reflection
OLC Innovate 2019 – Four Perspectives and a Podcast
Let's Gush (About Online Education)
Squad Goals Network | Go Long, John! on Meet the Editors – John Stewart
Squad Goals Network | Out of the Way on November is Here – Squad Goals Takeover Goes North
Squad Goals Network | Exploring Distant Fires – Reflecting on September's Social Media Takeover on Tide Pools and Oceans – September's Social Media Takeover with Angela Gunder
© Copyright Squad Goals Network


text:
"It is impossible to understand why they did it" – relatives and neighbors about a triple suicide in the Udmurt Republic
Udmurtia. Glazov. It is almost 200 kilometers from Izhevsk. On the last day of autumn – November 30, near the house №20 along the street Pekhtin gathered a crowd: discussed not politics, not gossip and not even pension reform. Talked about how and why a few hours ago I left the life of their neighbor: the grandmother, mother and granddaughter, 55, 35 and 8 years. Fell from the roof of flats. How? Why? From the place of events correspondent "Pravmir".
Photo: vk.com
Suicide is always whether a person has a choice?
Suicide – how to recognize it and can we prevent it?
Professor, Department of psychiatry Marina Kinkulkin: Suicide can be a reaction to the disease and the response to the staging of the terrible diagnosis
Can't stay away
"Why they decided to do it"
The Northern capital of Udmurtia, icy wind, not yet dawn. At the scene works operational investigative group from Izhevsk.
From news and official reports it is known very little – that criminal proceedings were instituted under article "Murder juvenile" and "Incitement to suicide". Police cordoned off from said hurriedly:
– Yes, died from a fall from the roof, are relatives, the investigation is ongoing, and politely asked to remove the camera and move.
City eye is quite small, if desired, it can be easily explored on foot in a few hours, it is divided into "old" and "new". In a new area – multi-storey buildings, in the old – mostly five-story building, another of Stalin's plan. The tragedy occurred in the "new" Glazov.
In the evening there was a lot of people, the area was cordoned off, investigators interviewed witnesses and neighbors. People didn't disperse and could not hold back the tears. Very, very sorry, especially the girl. It-for what?! – says a local resident returning from walking Nordic walking.
A number of small cafes. In the next house lived the mother of Anna. The waitress of the cafe tells everybody about the deceased.
Her baby girl with my in parallel classes studied. Pretty girl, humble, friendly. A couple of years ago Anya with a nice guy I met, moved in to live with him (marital status unknown men – approx.ed.), son gave birth to him. In the "old town" lived with his parents and sister-in-law. I often saw them with the stroller.
As they say, yesterday afternoon, Anna and their children came to visit my mom, my brother was at work. Why they decided to do it, I can not understand. Leaving a baby at home, climbed to the roof. They say they have the key to the door was. Like was no reason. Note? Yes, there were several notebook pages were seized by the police. By the way, the key, locking the door leading to the roof, in the pocket of my grandmother found. About credits I don't know… And you ask about it at work – Anya here and there, in a supermarket by the seller before the decree worked.
Ul. Pekhtin, 20. The same house
"Ne'er was, no other reason"
Anton, Anne's brother, picked up the phone almost immediately. The voice of the young and very tired to answer the questions reluctantly, but agreed:
The child is now with her father and his parents, they love him and care about him. Groom your sister loved, though, and fought often. Why go to such – I don't know. Unlucky they both were, no other reason.
The store where Anna worked, and the school in which she studied her daughter, – in two steps.
Shoppers at the supermarket is almost there. Colleagues remember Anna, voice shaking. Wonder what's on the scene for some reason no one brought flowers.
Is it the day we came in this morning, everything was fine. And last Friday, two cakes I bought, they together celebrated the birth of Alexei, the father of her youngest son. We were waiting for it a decree go out: hardworking, accurate, Executive – good work.
And social networks I don't know who calls her crazy. In childhood may have been some small problems, the mother took her to the psychiatrist, But Anna was quite adequate girl. Maybe not happily formed her life: one daughter was raised, but she finally met a man, loved him and everything changed. No particular material there were no problems, we'd know. Mother-in-law financially helped the mother, too, she in HCS worked.
In high school, where he studied wick elementary school on Saturday did not learn. The janitor of the school – an elderly woman – said that, in the words of Vika's teacher, she was one of the best students of the class, and even won prizes in competitions in draughts.
And little brother Vicky is now living with his grandmother and dad in the "old eyes," a five-storey building, near the train station. Neighbor Tatiana – she lives in the same building with family Ani, said the family is very decent and quite wealthy, she already knows. Anya in the family was received with cordiality, the grandmother of a grandson doted, the girl also loved.
From the porch entrance of the house 20 school No. 11, where he studied Vic
"The doors of the temples opened at any time"
Spaso-Preobrazhensky Cathedral – the Cathedral, the city of Glazov. People call it "temple of Freedom" in the name of the Central square of the city where it is located, and, of course, is its decoration: pleasing to the eye bright red and white walls and Golden domes, crowning the green roof. Here, on the second floor there is a reception of the Bishop of Glazov and Igrinskaya Victor.
The Bishop conducted immediately after a series of closed doors all the official authorities, I did not expect so easy to get an appointment.
The Bishop of Glazov and Igrinskaya Victor. Photo: eparhia-glazov.cerkov.ru
With a similar tragedy when life itself deprive the representatives of three generations, I was faced for the first time. It is obvious that the child was the innocent victim of adult problems that seemed unsolvable. Whether these mental health problems or were of social character – experts will understand. Alas, often people are closed in their little world, but the door of churches opened at any time… the Person in distress, always here to listen. I often meet and talk with people, and even the most seemingly hopeless situation, the output is, the main thing – to appeal, not to withdraw.
In mid-September, the clergy of the diocese of Glazovskiy almost all of them participated in training workshops "Unite, communicate openly. Take care of each other" for the prevention of suicidal behavior, which were organized by experts of the Republican clinical psychiatric hospital.
Near the temple, where we talked with the Bishop, the volunteers handing out red ribbons, Recalling that today is the Day to fight AIDS. Along the shore Bonnets river walk, and ride with hills. It's getting dark.
Irina Atova, Udmurtia
What is behind the tragedy – opinions of experts
Marina Panfilova, suicidology, candidate of psychological Sciences:
"Suicide is a multifactorial phenomenon. If the decision to part with life takes a whole family, obviously, the initiative comes from adults. To explain what happened in the Udmurt Republic, we can not, if only because it is necessary to understand the situation. If we talk about family suicide theory, he often becomes a consequence of affective reactions. Quite often such solutions are connected with religious beliefs typical of sects: the family goes to "a better world". However, such cases do not give an idea of a healthy family.
It is possible that the family in the Udmurt Republic are unable to adapt to her conditions. On the background of mental disorders or in the background of grief, for example, associated with the loss of a loved one, people have a desire to resolve their problems.
No one dares to comment on the situation clearly, saying, for example, that the cause of the tragedy is the economic situation, sectarianism, mental disorder or affect. The reasons can be a thousand. It's like a Rubik's cube, which is formed in a specific pattern. Again, the essence of family suicide usually comes down to the inability of the family to adapt to certain current social circumstances".
Vadim the romanche fracture zone area psychiatrist, psychotherapist, suicidology:
"When talking about a family suicide, then it means an extended suicide. As a rule, it is a consequence of social neblagopoluchnomu. To comment on the situation in Udmurtia not only quickly, but also difficult: too many questions. Who was and what was mother? That she was forced to do so? What is that grandma? And that it could force to rush with her granddaughter, then? Do not understand the situation, to comment on anything. Maybe a grandmother and her granddaughter wasn't jumping for the mother, and slipped when he tried to stop her. How do we know?! It is not excluded that this is all an accident. To understand this should be the result. You see, in life everything happens. Life in General is pretty tough stuff. Economic, psychological, psychiatric problems and even affect may be the cause of such actions.
But we need to understand more advanced suicide is always an exceptional case, a rarity. More importantly — every person who committed suicide, five to eight people injured. It's relatives, relatives, friends. All those for whom the question "what if?", "how?" remains unanswered. For them it is a severe stress disorder that can last for the later years and lead them to thoughts or attempts of suicide."
Recorded Darya Rowena
The high rate of suicides among representatives of Finno-Ugric peoples, including the Udmurts, were noted in the Soviet era. The capital of Udmurtia Izhevsk then even called the capital of the of suicide. In the second half of 50-ies in the Udmurt Republic, annually committed about 400 suicides, and early 70s – 800 in the early 80's- more than a thousand. During the anti-alcohol campaign in 1985, the figure dropped sharply, and then went upwards, reaching in 1995 1257 cases. With 80-ies of the Udmurt Republic among the five Russian regions with the highest suicide rate.
In the late 90-ies of the Institute. The Serbian has dedicated a whole study of the problem of suicide among Finno-Ugric peoples. "The persons of the Finno-Ugric nationalities – 94.9 suicide cases per 100,000, which is 2.2 times higher than among the Slavs (41.5 per 100 000) was reported by the study psychiatrist, doctor of medical Sciences, Professor Boris polozhy. – The prevalence of suicides at the Finno-Ugric peoples has increased in recent years by 1.6 times, and the Slavs remained stable. It very clearly shows a higher predisposition of the Finno-Ugric peoples to suicidal response."
The reason for this response, scientists set definitely could not. However historian Vladimir Vladykin of the Udmurt University believes that local have special character — they are reserved, even slow, but everything inside is literally "burning," often, negative emotions Udmurt pay for themselves, which sometimes leads to suicide. The Professor believes Udmurts vulnerable,"glass": under the blows of fate they don't bend and break. Udmurtia is important the opinions of others if they say bad, it can lead to tragedy.
Previous Previous post: The Primate of the UOC: When a person leaves sin, the Lord gives him the grace
Next Next post: "It's not genetics, and trauma" – 5 main features of orphans


text:
Q: Python scipy fsolve "mismatch between the input and output shape of the 'func' argument" Before I go into my problem, I've searched the relevant threads on stackoverflow with the same problem:

*

*input/output error in scipy.optimize.fsolve

*Python fsolve() complains about shape. Why?

*fsolve - mismatch between input and output

*I/O shape mismatch when using scipy.optimize.fsolve on 2-dimensional anonymous function array variable
From what I understand reading about this error,

raise TypeError(msg)
  TypeError: fsolve: there is a mismatch between the input and output shape of the 'func' argument 'fsolve_function'

The issue is that the shape of the input and output are not the same.
In my code example below, I have the following:

*

*input, initialGuess (the starting estimate to be used in the fsolve function in scipy.optimize). The input, initialGuess has 3 starting estimates for coordinates x,y and z. Therefore I expect my starting input estimate to have always three inputs.

*output, out (non-linear simultaneous equations). In this example I have 4 non-linear equations.

*scipy.optimize.fsolve raises the error highlighted above, because the input and output do not have the same shape. In my particular case, I want my input to always have three values (to guess the initial starting points of x, y, and z). The output in this case has 4 non-linear equations to solve using the initial input estimate.

*Side note: Using the same input and output shape, eg. input shape of 3 [x, y, z] and output of 3 non-linear equations, fsolve will do the calculation accordingly. I'm just wondering how could you extend fsolve to use let's say equal or more than 4 non-linear simultaneous equations with just 3 input initial estimates?

*Code below:
from scipy.optimize import fsolve

def fsolve_function(arguments):
    x = arguments[0]
    y = arguments[1]
    z = arguments[2]

    out = [(35.85 - x)**2 + (93.23 - y)**2 + (-39.50 - z)**2 - 15**2]
    out.append((42.1 - x)**2 + (81.68 - y)**2 + (-14.64 - z)**2 - 27**2)
    out.append((-70.90 - x)**2 + (-55.94 - y)**2 + (-68.62 - z)**2 - 170**2)
    out.append((-118.69 - x)**2 + (-159.80 - y)**2 + (-39.29 - z)**2 - 277**2)

    return out

initialGuess = [35, 93, -39]
result = fsolve(fsolve_function, initialGuess)
print result

A: fsolve is a wrapper of MINPACK's hybrd, which requires the function's argument and output have the same number of elements. You can try other algorithms from the more general scipy.optimize.root that do not have this restriction (e.g. lm):
from scipy.optimize import fsolve, root

def fsolve_function(arguments):
    x = arguments[0]
    y = arguments[1]
    z = arguments[2]

    out = [(35.85 - x)**2 + (93.23 - y)**2 + (-39.50 - z)**2 - 15**2]
    out.append((42.1 - x)**2 + (81.68 - y)**2 + (-14.64 - z)**2 - 27**2)
    out.append((-70.90 - x)**2 + (-55.94 - y)**2 + (-68.62 - z)**2 - 170**2)
    out.append((-118.69 - x)**2 + (-159.80 - y)**2 + (-39.29 - z)**2 - 277**2)

    return out

initialGuess = [35, 93, -39]
result = root(fsolve_function, initialGuess, method='lm')
print(result.x)

Incidentally, it cannot find the actual zero --- is there supposed to be one at all?
You can also force fsolve to use your function if you supply it an initial guess with a "bogus" fourth variable:
initialGuess = [35, 93, -39, 0]

but I'm not sure how reliable are the results in this case.

redpajama_set_name: RedPajamaStackExchange


Are you looking to find Tennessee office space? OfficeFinder's Tennessee office space experts will help you by matching your needs with available office space in Tennessee – and it is a FREE service. We can help you whether you want Tennessee office space for rent, lease or purchase, and we do much more.
OfficeFinder's Tennessee office space experts will help you throughout the entire process of securing office space in the location you prefer. We'll assist during negotiations with property owners, helping you avoid mistakes that can cost you dearly. We service all the large Tennessee markets and many of the submarkets. You will be glad you allowed Tennessee OfficeFinder to assist you in locating business space in the spot you love.
The cites in Tennessee that we can help you find office space include: Memphis, Nashville, Knoxville, Chattanooga and Brentwood along with their submarkets.
Our process is easy; just fill out and submit the form on this page with some simple facts about your needs. You'll quickly be contacted by a LOCAL Tennessee office space expert, one who knows the business market in the spot you prefer. Your representative will discuss with you the complete details regarding your needs and desires for business space, match available properties and you'll visit only those you prefer. Your OfficeFinder expert will also assist in negotiations with property owners through signing the final agreement. Don't go it alone; allow OfficeFinder to help you avoid potentially expensive errors.
Tennessee is part of the Deep South but it is a state that contributed soldiers to both the Confederate and Union troops in the Civil War, making it quite unique in history and creating many historic sites such as Andrew Jackson's Hermitage, Shiloh National Military Park, Stones River battlefields, Chickamauga and Chattanooga National Military Park and more. Nashville is the second largest city, after Memphis, and the capital of the state. The Great Smoky Mountains attracts visitors annually along with the Appalachian Trail, Dollywood, Pigeon Forget, Country Music Hall of Fame, Jack Daniel's Distillery, Elvis Presley's Graceland and others. States parks abound with 23 parks covering over 132, 000 acres.
The Tennessee economy is strong with major industries including manufacturing, tourism and agriculture. Tennessee exports chemicals, electrical equipment and transportation equipment. Whether you own an existing business and wish to relocate or are beginning a brand new venture, Tennessee is ready to offer you opportunities for success. Don't miss out on the chance to secure great Tennessee office space with the assistance of OfficeFinder.


text:
Shoreline Biosciences Is Positioned to Be a Category Leader
To win the war on cancer through transformative cellular immunotherapies
To change the lives of patients and their families living with cancer by developing safe, highly effective and accessible iNK and iMAC cell therapies
We Are Committed to Scientific and Clinical Excellence and Are Passionate About Bringing Transformative Therapies to Patients in Critical Need
Phyllis balan
Vice President, People and Culture
Charles Calderaro III
Bjorn Dahle
Vice President, Smart Manufacturing
Pinky Doshi
Vice President, Regulatory Affairs
Mohammad El-Kalay, Ph.D.
Senior Vice President, CMC Drug Development
Scott Forrest, Ph.D.
Chief Business Officer
ROBERT HOLLINGSWORTH, PH.D.
Vanessa Jacoby, CPA
Lisa Melia
Vice President, Clinical Operations
Steven Neben, Ph.D.
Vice President, Alliance and Project Management
Paschalis Sideras, PH.D.
Vice President, Discovery Immunobiology
Kleanthis G. Xanthopoulos, Ph.D.
Huang Zhu, PH.D.
Dan S. Kaufman, M.D., Ph.D.
STEVEN HOLTZMAN
Marios Fotiadis
Christopher Fuglesang, Ph.D., J.D.
Kimberly J. Manhard
Frank YU
Co-Founder, Board Member, and Chair of SAB
William Sandborn, M.D.
Co-Founder & Advisory Board Member
Travis S. Young, Ph.d.
Scott Antonia, M.D., Ph.D.
SILKE PAUST, Ph.D.
Judith Shizuru, Ph.D.
Together Let's Push the Boundaries of Scientific Innovation
10220 Sorrento Valley Road
Email Shoreline
©2022 Shoreline Biosciences. All Rights Reserved.
Mr. Yu is the founder, CEO and CIO of Ally Bridge Group, a leading global life science-dedicated investment group. Mr. Yucarries a strong track record as an investment manager across multiple funds and strategies with investments in the U.S., China and Europe.
Mr. Yu started his career in New York, then worked in Hong Kong for over two decades. Previously, Mr. Yu was Managing Director and Head of China Investments at Och-Ziff Capital Management (OZ), a leading global hedge fund, where he made some of OZ's largest and highly successful investments.
Prior to OZ, Mr. Yu was a Managing Director at Goldman Sachs in Hong Kong, where he headed several business units and played instrumental roles in some of the most important restructuring, IPO and M&A transactions of leading Chinese companies. Mr. Yu also advised leading global institutions on their China and Asia strategies and transactions. Before Goldman Sachs, Mr. Yu worked at Moody's in New York, and then Credit Suisse in London and Hong Kong.
Since 2010, Mr. Yu has founded, launched and managed multiple funds covering venture, growth, buyout and hedge fund investing from China to U.S. to Europe.
Mr. Yu excels in originating and executing major investment themes such as global life science investing, which has become the primary focus of Mr. Yu and Ally Bridge, creating high-impact deals such as the landmark US$3.3 billion WuXi Pharmatech. He has expertise in cementing strategic transactions between emerging players and industry leaders across the U.S., China and Europe.
Dr. Zhu has over a decade of experience in developing stem cell derived therapeutics and joined Shoreline Biosciences since January 2021, where he built a talented and nimble research team, oversees iPSC derived NK (iNK) cell platform development, initiation of therapy programs, and external partnerships. Prior to joining Shoreline, Dr. Zhu was focused on developing cord blood derived, allogenic NK cell product at Takeda, Cell Therapy. Previously, he had held multiple research positions of increasing responsibilities at Eli Lilly and Company China R&D center.
His studies as a post-doctoral fellow were the first to uncover the crucial function of cytokine-inducible SH2 containing protein (encoded by gene CISH), a critical negative regulator of NK function in human iNK cells. CISH knock out iNK cell is now the core cell engineer of Shoreline's iNK cell products with enhanced durability and activity for optimal performance in fighting against cancers. In addition, he also led the development of high-affinity, non-cleavable CD16 iNK cell product (hnCD16-iNK) to augment antibody-dependent cellular cytotoxicity (ADCC) which is now in clinical development, showing very promising clinical efficacies in patients with B cell lymphoma.
Dr. Zhu has published over 20 papers in prestigious scientific journals. He received a B.A. in Biochemistry from Tianjin University, a Ph.D. in Molecular Biology and Developmental Biology from Shanghai Jiao Tong University, China, and was a Postdoctoral Fellow at University of California, San Diego, California.
Prior to joining Shoreline, Mr. Calderaro served as Global Head of Technical Operations for Kite Pharma, a pioneer in cell therapy development, where he was responsible for leading all aspects of Kite's technical operations, including process development, CMC regulatory, manufacturing, quality, supply chain, engineering, end-to-end optimization of commercial and pipeline products.
While at Kite, Mr. Calderaro oversaw manufacturing of CAR-T cell therapy products at an unparalleled commercial scale. Prior to Kite, Mr. Calderaro was Senior Vice President, Global Manufacturing at BioMarin Pharmaceutical, where he was responsible for the strategic oversight and leadership of a diverse international manufacturing network, which utilizes small molecule, oligonucleotide, biotechnology, and gene therapy technologies to deliver an innovative portfolio of clinical and commercial products to patients. Before that, he spent fourteen years at Genentech in roles of increasing responsibility in product management, engineering, and manufacturing.
Early in his career, Mr. Calderaro spent time at Alcon, a division of Novartis, and operations. Mr. Calderaro received a Bachelor's degree, Electrical Engineering from the University of Notre Dame, a Master's Degree, Nuclear Engineering from the US Naval Nuclear Power School and a Masters of Business Administration from Texan Christian University.
Phyllis Balan, MBA has over 20 years' experience in all aspects of human resources, including talent management, talent acquisition, total rewards, and organizational development. She has been a leader and consultant with several Fortune 500 companies in technology and life sciences, including Biogen. Ms. Balan previously led the HR function at Sotera Wireless, AnaptysBio and Plexium.
Ms. Balan holds a Bachelor of Science and a Master of Business Administration from Michigan State University as well as an MA from San Diego State University in Educational Technology.
Paschalis Sideras brings more than three decades of global experience in immunology research within both academia and the pharmaceutical industry to Shoreline. Prior to joining Shoreline, Dr. Sideras served as Director of the Centre for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation at the Academy of Athens. Before that, he served in roles of increasing responsibility at AstraZeneca in the R&D team in Lund, Sweden. Prior to AstraZeneca, Dr. Sideras served in several academic roles including Assistant Professor of Cell and Molecular Biology and Visiting Scientist where he oversaw teams of graduate students and post-doctoral fellows across many scientific disciplines. He holds a Dr. Med. Sci. in Immunology, from the Karolinska Institute in Stockholm, Sweden and a Docent in Molecular Immunology, from Umeå University in Umeå, Sweden.
Lisa Ann Melia
Lisa Ann Melia brings a wealth of expertise as a clinical research professional with significant experience in the planning and execution of clinical studies from Phase 1 through Phase 3, in the US, Europe, Asia and Latin America to Shoreline. Prior to joining Shoreline, Ms. Melia served as Vice President, Clinical Operations at Indaptus Therapeutics, where she was responsible for all clinical activities related to a Phase 1 first-in-human study in patients with advanced solid tumors. Prior to that, she was Vice President, Clinical Operations for MEI Pharma, Regulus Therapeutics, and the California Institute for Biomedical Research (Calibr). Previously, she held clinical positions at Pfizer Worldwide R&D, Icon Clinical Research, Ceregene and Acadia Pharmaceuticals. Ms. Melia began her industry career with Boehringer Ingelheim Pharmaceuticals. Ms. Melia holds an MA in Psychology from the University of Tennessee at Knoxville and a BA in Psychology from Trinity University.
Pinky Doshi brings more than two decades of global regulatory experience within the pharmaceutical industry to Shoreline. Prior to joining Shoreline, Ms. Doshi served as Senior Director, Regulatory at Bristol Myers Squibb, BMS, (formerly Celgene prior to 2019), Cell Therapy Franchise where she was the global regulatory lead on the AbecmaTMb program and was the regional US lead providing strategic guidance for the first BCMA CAR T for relapsed or refractory multiple myeloma. In addition, she served as the global regulatory lead for early and late-stage solid tumor oncology programs. Prior to BMS, Ms. Doshi served in several regulatory positions across multiple therapeutic areas in early and late-stage therapeutics at Hoffmann-La Roche, Schering Plough Research Institute, and Johnson & Johnson Pharmaceutical Research & Development. Prior to that, Ms. Doshi held regulatory positions at Halsey Drug Company, Quest International, and TAP Pharmaceuticals. Ms. Doshi holds a Bachelor of Science, Cell and Structural Biology from the University of Illinois and a Master of Science, Biotechnology from Northwestern University.
Dr. Hollingsworth joins Shoreline from Pfizer, Inc., where he served as Chief Scientific Officer and Vice President of Cancer Vaccines and Immunotherapeutics. While at Pfizer, Dr. Hollingsworth led a large oncology research team who successfully advanced five programs into clinical development and implemented several innovative new therapeutic approaches. Prior to Pfizer, he was Senior Director, Oncology Research at MedImmune where he led and advanced a large portfolio of more than twenty programs, including CAR-T programs partnered with Juno Therapeutics and the National Cancer Institute, and contributed to the approval of durvalumab (IMFINZI®). Before that, he held several R&D positions of increasing responsibility at GlaxoSmithKline (GSK), Pharmacia and Upjohn.
Dr. Hollingsworth is a decorated scientist with several prestigious awards and honors including the GSK Great Science Award, given to the top R&D scientist each year, and a Research Excellence Team Award at Pfizer for developing an innovative new therapy. Dr. Hollingsworth has published over 50 papers, co-authored over 200 abstracts presented at scientific meetings, and is a co-inventor on over 15 awarded patents. He received a B.A. in Biology and Physics from the University of California, Berkeley, a Ph.D. in Biochemistry, Biophysics, and Genetics from the University of Colorado, and was an American Cancer Society Postdoctoral Fellow at the University of Texas Institute of Biotechnology in San Antonio, Texas.
Simos Simeonidis, PhD
Simos Simeonidis, PhD is Co-Chief Executive Officer, Co-Chief Investment Officer and Managing Partner of Ally Bridge Group (ABG), a global healthcare-dedicated investment group focused on innovations across all life sciences segments through investments in both private and public companies. He is also President and Portfolio Manager for Ally Bridge Group's public equity strategy.
Dr. Simeonidis's experience spans over 25 years across academia, biopharma, equity research and investment management. Most recently, he was Partner, Senior Managing Director, Co-Head of Research and Portfolio Manager at Sarissa Capital Management, an investment manager focused on shareholder activism within the healthcare sector. Before that, he was Managing Director and Senior Biotechnology Analyst at the Royal Bank of Canada (RBC) and has spent over a decade covering the biopharmaceutical space in several investment banks, including Cowen & Company and Morgan Stanley. Dr. Simeonidis began his biopharmaceutical industry career in Business Development & Licensing and Strategic Planning at Novartis. Before moving to industry, he was a faculty member in Medicine at Harvard Medical School and the Beth Israel Deaconess Medical Center, where his work focused on the transcriptional regulation of gene expression.
Dr. Simeonidis holds a BS in Biology from Loyola University of Chicago and MA, MPhil and PhD degrees in Cellular, Molecular and Biophysical Studies from Columbia University's Vagelos College of Physicians and Surgeons. He completed his postdoctoral fellowship at the laboratory of Professor Tucker Collins at Harvard Medical School and the Brigham and Women's Hospital. Dr. Simeonidis also holds an MBA in Healthcare Management from the Wharton School of the University of Pennsylvania.
Prior to joining Shoreline, Dr. Forrest was Chief Financial Officer of Autobahn Therapeutics where he was responsible for corporate development, portfolio planning and financial strategy. Prior to Autobahn, Dr. Forrest served as Chief Operating Officer and Chief Financial Officer at Inception Therapeutics, a Versant Ventures discovery engine focused on building and operating transformative biotech companies. In this role, he played an integral leadership role in multiple companies including Lycia Therapeutics, Pipeline Therapeutics, Chinook Therapeutics and Ventus Therapeutics. Prior to Inception, Dr. Forrest was a Co-Founder and Vice President of Operations and Corporate Development at BlackThorn Therapeutics. Earlier, he was Vice President of Business Development at The Scripps Research Institute, where he oversaw the creation and launch of more than 15 new biotech companies and led the negotiation and management of over $200 million in corporate alliances. He also held director or board observer positions with several companies including Zyngenia, Abide, Padlock and Epic Sciences. Dr. Forrest started his career at the University of North Carolina where he led the restructuring, expansion and management of the life sciences licensing team. He also served as an entrepreneur in residence at UNC and was a central part of the successful launch of multiple startup companies such as Epizyme. Dr. Forrest holds a B.S. in biochemistry from the University of Calgary and a Ph.D. in pharmacology from the University of Virginia.
Judith Shizuru is a Professor of Medicine (Blood and Marrow Transplantation [BMT]) and Pediatrics (Stem Cell Transplantation) at Stanford University. Dr. Shizuru is a member of the Stanford BMT faculty, the Stanford Immunology Program, and the Institute for Stem Cell Biology and Regenerative Medicine. Dr. Shizuru received a Bachelor's degree from Bennington College and an M.D. and Ph.D. from the Stanford University School of Medicine. She trained as a resident in adult internal medicine at the University of California, San Francisco, and in the sub-specialty of hematology at Stanford. Dr. Shizuru has been attending on the Stanford Blood and Marrow Transplantation clinical service since 1997, and she oversees a research laboratory. Her laboratory is focused on understanding the cellular and molecular basis of resistance to engraftment of transplanted allogeneic hematopoietic cells, and the way in which bone marrow grafts modify immune responses including the induction of immune tolerance. Dr. Shizuru has over 150 publications in the fields of immunology and hematopoietic cell transplantation. She is the scientific co-founder of Jasper Therapeutics, Inc, a member of the Board member and Chair of Jasper's Scientific Advisory Board.
Dr. Travis Young is the Vice President of Biologics at Calibr, a division of Scripps Research and holds an appointment as Professor of Chemical Biology in the Department of Chemistry at Scripps Research. He received a BS in biochemistry from Boston College and a PhD in chemical biology from The Scripps Research Institute as an ARCS scholar. At Scripps, his work focused on the development of unnatural amino acid incorporation methodologies to improve the properties of therapeutic proteins. This work was foundational for the development of programs in the Calibr pipeline today, including a bispecific antibody for prostate cancer which will enter clinical trials next year. After receiving his PhD, he completed a postdoc at Harvard Medical School with an NIH fellowship, in the department of Biological Chemistry and Molecular Pharmacology with Dr. Christopher T Walsh.
Dr. Young was a member of the founding group of principal investigators at Calibr and serves as the lead investigator on multiple bench-to-bedside antibody and cellular therapy-based programs. Dr. Young maintains a research group focused in the development of novel therapeutics at the interface between protein engineering and synthetic biology. This research spans multiple disease indications including cancer, autoimmune, metabolic disorders, and infectious disease. His work has been highly awarded and received support from the Wellcome Trust, NIH (National Cancer Institute), Department of Defense, Mesothelioma Research foundation, American Cancer Society, among others. His work has resulted in numerous publications and patents with >2250 citations in the past 5 years. Dr. Young has led two programs from concept into first-in-human clinical trials while at Calibr: a bispecific antibody for prostate cancer and a unique switchable CAR-T cell therapy platform for blood cancer.
Scott Antonia, MD, PhD, joined the Duke Cancer Institute in 2019, where he directs the DCI Center for Cancer Immunotherapy, and is a member of the Thoracic Oncology disease group as Professor of Medical Oncology.
After completing his medical oncology training and post-doctoral fellowship in the Flavell Lab at the Yale University School of Medicine, he joined H. Lee Moffitt Cancer Center in 1994. There, he served as chairman of the Department of Thoracic Oncology.
Antonia is recognized as a global leader in the development of immunotherapy for lung cancer. He served as the global principal investigator for the practice-changing Pacific study, which established, as the new global standard of care, anti-PDL1 as consolidative therapy after combined chemo-radiation therapy for locally advanced non-small cell lung cancer. He was also the lead investigator of trials that established the clinical activity of immunotherapy for small cell lung cancer.
For the past 27 years, Antonia has directed a translational research program that's overall goal is to develop immunotherapeutic strategies for the treatment of cancer patients; using tumor vaccines or adoptive T cell therapies in combination with immunomodulatory strategies designed to thwart the immunosuppressive mechanisms used by tumors to evade T cell mediated rejection. He has extensive experience in conducting early-phase clinical trials testing therapeutic tumor vaccines, adoptive T cell therapies and immunomodulatory antibodies.
Research in Dr. Paust's laboratory at the Scripps Research Institute seeks to elucidate the molecular mechanisms causal to murine and human NK cell-mediated adaptive immunity. Our long-term goal is to use this knowledge to develop novel anti-viral and anti-tumor vaccines or NK cell-based infusion products. Approaches include cell biology, molecular biology, and immunology experiments in mice, humanized mice, and using human specimens.
Trisha Fitzmaurice
Head of People & Culture
Mrs. Fitzmaurice is an HR professional with over 8 years' experience mostly in life science/pharmaceutical companies. Before joining Shoreline, she has held HR roles at Adamis Pharmaceuticals and US Compounding. Mrs. Fitzmaurice holds a Bachelor of Arts degree from Indiana University – Bloomington and a Juris Doctorate from Thomas Jefferson School of Law.
Steven Neben, PhD has more than two decades of experience in project and alliance management in the biopharmaceutical industry at both small and large companies. Prior to joining Shoreline, Dr. Neben served as Executive Director, Project and Alliance Management for Regulus Therapeutics where he was responsible for the management of drug discovery and development partnerships with pharmaceutical partners and management of the research stage project portfolio of RNA therapeutic programs. Prior to Regulus, Dr. Neben was Senior Director, Project and Alliance Management at AnaptysBio, Director, Project and Alliance Management at Xoma and principal scientist at Bayer Pharmaceuticals. Dr. Neben holds a BA and PhD from the University of California, Berkeley.
Boyan Litchev, M.D.
Senior VP & Head of GCD
Boyan Litchev, MD brings to the company more than two decades of global experience in the pharmaceutical and biotechnology industry, with significant experience in the development of CAR-T, nucleotides (RNA), peptides, small molecules and gene therapies for various diseases.
Dr. Litchev joins Shoreline from Poseida Therapeutics, where he was Head of Clinical Development Oncology and was responsible for leading the company's CAR-T programs in solid tumors. Before that, he was Executive Medical Director, Head of Clinical Development Oncology for Halozyme Therapeutics, and Executive Medical Director, RNA-targeted therapies Clinical Development for Akcea Therapeutics, a wholly owned subsidiary of Ionis. Prior to Akcea, Dr. Litchev worked at Takeda (formerly Shire) where he led clinical development programs in gene therapy and hematology. Dr. Litchev previously held roles of increasing responsibility at Ferring Pharmaceuticals, Syneos Health (INC research), IQVIA (Quintiles) and University of California San Diego. Dr. Litchev is a board-certified physician in Obstetrics and Gynecology. Dr. Litchev received his MD degree from Medical University Plovdiv. Prior to joining the pharmaceutical industry, he has treated patients and conducted clinical research.
Bjorn Dahle, MBA has extensive experience in various industries in advancing products through manufacturing to sales and marketing. Prior to joining Shoreline, Mr. Dahle was Co-founder and CEO of Inspire Solutions LLC, CEO of VersaCall Technologies and President of KIC, a technology company. Prior to that, he held key executive, global roles at St. Bernardo Softward and MPM. Mr. Dahle holds an MBA in marketing from San Diego State University and a bachelor's degree in mechanical engineering from Norwegian University of Science and Technology.
Senior Vice President, CMC Drug Delivery
Dr. El-Kalay joined Shoreline in June 2021 as Senior VP and Head of CMC (Chemistry, Manufacturing, and Control). Dr. El-Kalay has over three decades of experience in global biopharmaceutical operations, including key leadership roles in cell therapy companies where he led the successful translation of several cell therapy candidates into late-stage clinical development, as well as developing a T-cell purging device that was later marketed.
Dr. El-Kalay holds a B.Sc., M.Sc. and Ph.D. from Strathclyde University in Glasgow, UK.
Dr. El-Kalay joins Shoreline from Poseida Therapeutics, where he was VP, Technical Operations and was responsible for developing processes to manufacture their autologous and allogeneic CAR-T cell products. Prior to Poseida, he was SVP, Technical Operations for San Bio, Inc., directing development of manufacturing processes of their gene modified allogeneic mesenchymal stem cells to treat CNS diseases.
Before that, he held senior technical and leadership roles at Sangamo Therapeutics, Stem Cells, Inc., and was Founder, President, and CEO of EyeCyte, an autologous cell therapy company. He also held senior leadership R&D and Technical Operation roles at MicroIslet, Telos Pharmaceuticals, MorphoGen Pharmaceuticals, Osiris Therapeutics, SyStemix, and Applied ImmuneSciences.
Kimberly is a biopharmaceutical executive with more than 25 years of drug development, regulatory affairs, quality assurance, pharmacovigilance and pharmaceutical operations experience.
Ms Manhard has served as the Executive Vice President of Drug Development for Heron Therapeutics, Inc. (Heron) since January 2016, after serving as a board director in 2014 and 2015. She rejoined the Heron board in November 2019. Since 2020, Ms Manhard has also served as a board director of Toragen, Inc. (non-public company) and of InhibRx, Inc. (public company), which are focused on the research and development of new treatments for cancer.
From 2008 to 2016, Ms Manhard served as Senior Vice President of Regulatory Affairs and Development Operations at Ardea Biosciences, Inc. (Ardea), a wholly-owned subsidiary of AstraZeneca PLC, and led the US, EU and rest of world registration activities for Zurampic® (lesinurad) for the treatment of hyperuricemia associated with gout. At the time of joining Ardea in 2006, Ms Manhard also oversaw general corporate operations and HIV and Oncology drug development. Prior to joining Ardea, Ms. Manhard was President of her own consultancy firm, Vice President of Regulatory Affairs for Exelixis, Inc. and held multiple regulatory positions at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company, supporting development and commercialization of anticancer and antiviral products, including Viracept® (nelfinavir).
Ms Manhard was also previously with Bristol-Myers Squibb Company in regulatory affairs, responsible for oncology compounds, including Taxol® (paclitaxel) and infectious disease compounds, including Videx® (didanosine) and Zerit® (stavudine). Ms. Manhard began her industry career in clinical research with Eli Lilly and Company and G.H. Besselaar Associates (Covance Inc.). Ms. Manhard is a member of the board of trustees for the Fleet Science Center. She received a B.S. degree in zoology and a B.A. degree in French from the University of Florida.
Dr. Fuglesang is a Co-Founder and Managing Director of Boxer Capital, LLC.
After joining Tavistock Group in 2005, Dr. Fuglesang helped scale Tavistock Group's public healthcare investing activities with Boxer Capital. Dr. Fuglesang assists in managing the firm's research team, deal structuring, and securities compliance.
Dr. Fuglesang is a Member of the Board of Directors of CiVi Biopharma, Inc., BCTG Acquisition Corporation (NASDAQ: BCTG) and previously served on Pandion Therapeutics (NASDAQ: PAND) before its acquisition by Merck.
Earlier in his career, Dr. Fuglesang supervised a variety of transactions, including mergers and acquisitions, joint ventures, and other strategic collaborations in the healthcare sector.
Dr. Fuglesang brings with him years of experience in building and developing life science companies, previously founding, and holding board and executive management positions at multiple biotechnology companies.
Dr. Fuglesang holds a Doctorate degree in Chemical Physics from the University of California, Los Angeles, a Juris Doctor degree from the Boston University School of Law, and Bachelor of Science degrees in Chemistry and Physics from the University of California, Los Angeles.
Marios is an investor specializing in private equity globally with investments representing over $1 billion USD in committed capital.
Marios started his career in investment banking with SG Cowen in New York followed by a move to SG Capital Partners in 1998, where he began his career in private equity. There he focused on investments in growth and venture capital with an emphasis in healthcare and technology companies.
Following that he became the CEO of Achillion Pharmaceuticals Inc (NASDAQ "ACHN") where he completed a successful turnaround that culminated with an IPO on NASDAQ. Marios moved to Advent International in Boston where he was a partner with a focus on global investments in health care and life sciences.
Subsequently, he became Managing Partner of TVM Capital MENA, where he raised the first private equity fund in the MENA region dedicated to investments in health care and pharmaceuticals.
Since 2012, Marios has been responsible for managing investments of his family office, under Cerus Advisors. He is currently member of the Board of Directors of Stork Capital, an investment management company with offices in Geneva, Switzerland and Dubai.
His responsibilities involve sourcing, closing and managing direct investments in private equity as well as asset allocation and overseeing the selection of managers for the public side of the portfolio. Marios holds a BSc degree cum laude from University of Denver and an MBA from Columbia University in New York.
Ms. Jacoby has extensive experience in the biotechnology and life science sectors, having served as a senior financial executive of several private and public companies. Prior to joining Shoreline, Ms. Jacoby served as Chief Accounting Officer of Avidity Biosciences, Inc., where she led all corporate finance and planning activities and played a key role in the company's $300M Initial Public Offering in June 2020 and $100M Series C in October 2019. Prior to Avidity, Ms. Jacoby was Vice President, Finance at PharmAkea, which was acquired by Galecto in 2019. Prior to that, she served as a Director of Accounting and Controller at BCI, Inc. and held senior financial roles at Artes Medical and Verenium. Before joining industry, Ms. Jacoby was an auditor for Ernst & Young. Ms. Jacoby received her M.B.A. from National University and B.S. degree in Business Administration from Fundação Armando Alvares Penteado, Sao Paulo, Brazil. She is a Certified Public Accountant with the State of California (inactive).
Co-Founder and Advisory Board Member
Dr. Sandborn joined Shoreline as CMO in April 2021. Dr. Sandborn completed medical school and an internal medicine residency at Loma Linda University in Loma Linda California.
He completed a gastroenterology fellowship at the Mayo Clinic in Rochester, Minnesota in 1993.
From 1993-2010, he was on the faculty of the Mayo Clinic, rising to Professor of Medicine, Vice Chairman of the Division of Gastroenterology and Hepatology, and Associate Dean of Research for Intellectual Property and Industry Relations.
In 2011, he became a tenured Professor of Medicine, Chief of the Division of Gastroenterology, and Director of the Inflammatory Bowel Disease Center at the University of California San Diego.
Dr. Sandborn has published over 851 peer-reviewed articles including articles in the New England Journal of Medicine, Nature, Lancet, JAMA, Annals of Internal Medicine, and Gastroenterology. His h-index is 138.
He is a member of the editorial board for the New England Journal of Medicine. In 2019, he was awarded the Sherman Prize for his work in inflammatory bowel disease. He was a scientific co-founder of Santarus (acquired by Salix Pharmaceuticals in 2013, now Bausch Health), and currently serves as Chair of the Scientific Advisory Board for Prometheus Biosciences.
Co-Founder and Board Member
Steven is the Chair of the boards of Qihan Biotech and Camp4 Biotherapeutics, both private biotechnology companies.
Since January 2020, he has served as a Strategic Advisor to Decibel Therapeutics, where he served as the company's first president and chief executive officer and a board member from 2016—2020.
Prior to Decibel, from 2011 to 2016 he served as executive vice president, corporate development at Biogen, Inc., where he led eight new drug approvals.
Previously, from 2001 to 2011, Steve was the founder, chief executive officer and board chair of Infinity Pharmaceuticals, Inc., a cancer drug discovery and development company.
He was also, from 1994 to 2001, an early leader and the chief business officer of Millennium Pharmaceuticals, a pioneer in large-scale genetics and genomics.
From 1986 to 1994 he was a co-founder, board member and executive vice president of DNX Corporation, the first transgenic animal company.
He is a member of the board of directors of Molecular Partners, a member of the board of trustees of the Berklee College of Music, and a senior fellow at the Belfer Center for Science and International Affairs at the Harvard Kennedy School.
He was appointed by President Clinton to the National Bioethics Advisory Commission and he also served as a member and vice chair of the board of the Hastings Center for the Life Sciences.
He obtained his undergraduate degree in philosophy from Michigan State University and his graduate degree in philosophy from Oxford University, which he attended as a Rhodes Scholar.
Dr. Kaufman is a Professor in Department of Medicine, Division of Regenerative Medicine and Director of the Cell Therapy program at the University of California-San Diego (UCSD).
Following undergraduate studies at Stanford University, he completed a combined MD/PhD program at Mayo Clinic and a clinical residency and fellowship in internal medicine and hematology at the University of Wisconsin-Madison.
Dr. Kaufman is practicing clinical work in hematology and blood and marrow transplantation (BMT).
His research focuses on use of human induced pluripotent stem cells (iPSC) to study development of hematopoietic stem/progenitor cells, lymphocytes and other immune cells.
His studies as a post-doctoral fellow were the first to derive blood cells from human pluripotent stem cells.
In addition, His laboratory was the first to produce functional lymphocytes from human pluripotent stem cells.
Dr Kaufman's laboratory has pioneered strategies including novel NK-specific chimeric antigen receptors and other gene editing approaches that increase NK cell-mediated activity.
Dr. Kaufman also leads the Advanced Cell Therapy Laboratory (ACTL), a GMP facility at UCSD to translate novel cell-based therapies into clinical trials and continues to practice clinical work.
Kleanthis G. Xanthopoulos, Ph.D., is a serial entrepreneur with over 25 years of experience in biotechnology as an executive, company founder, chief executive officer, investor, and board member. He has founded five companies, introduced three life science companies to Nasdaq as CEO, and financed and brokered numerous creative multibillion strategic alliance and partnership deals with large pharmaceutical partners.
Dr. Xanthopoulos is a co-founder and Chairman & CEO of Shoreline Biosciences, a cell-therapy company focused on immunotherapies using intelligently engineered iPSC-derived allogeneic Natural Killer (NK) cells and Macrophages. He also serves as the Chairman of Stork Capital Life Sciences, a firm focused on building and investing in innovative biotechnology companies. He served as the President & CEO of IRRAS AB, a public (Nasdaq: IRRAS) MedTech company and as Managing General Partner at Cerus DMCC, an investment firm, from August 2015-2020. Dr. Xanthopoulos served as President and CEO of Regulus Therapeutics Inc. from its inception in 2007 until June 2015. Prior to that, he was a managing director of Enterprise Partners Venture Capital. Dr. Xanthopoulos co-founded and served as President and Chief Executive Officer of Anadys Pharmaceuticals, Inc. from its inception in 2000 to 2006 and remained a Director until its acquisition by Roche in 2011. He was Vice President at Aurora Biosciences (acquired by Vertex Pharmaceuticals, Inc.) from 1997 to 2000. Prior to joining the biotechnology industry, Dr. Xanthopoulos participated in The Human Genome Project as a Section Head of the National Human Genome Research Institute from 1995 to 1997 at the NIH. Prior to this, Dr. Xanthopoulos was an Associate Professor at the Karolinska Institute, in Stockholm, Sweden, after completing a Postdoctoral Research Fellowship at The Rockefeller University, New York. Dr. Xanthopoulos, an Onassis Foundation Scholar, received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden.


text:
<?php
	namespace jexm\controllers;

	class TestController extends Controller{

		public function __construct(){
			parent::__construct();
		}

		public function index(){
			return View::render('test');
		}
	}


14. CORTE CONSTITUCIONAL DE COLOMBIA, ¿TAN INCORRUPTIBLE COMO DEBERÍA SER?
6. PARTIENDO DE UN ANÁLISIS DEL COMPORTAMIENTO DE LOS MERCADOS DE VALORES: ¿ES ADECUADO LA IMPLEMENTACIÓN DE LAS NORMAS INTERNACIONALES DE INFORMACIÓN FINANCIERA EN NUESTRO PAÍS?


text:
Home › News › May 2019
Albany Museum of Art begins Art Lovers Book Club
Staff Report From Albany CEO
Those who love art and good books will have a new opportunity to discuss both at the new AMA Art Lovers Book Club.
The club's first meeting is at 6 pm on Tuesday, May 21, 2019 at the Albany Museum of Art's Willson Auditorium. There is no cost to participate as AMA staff and fellow book lovers in the area read and talk about books related to art, artists and art museums.
The first selection is I am Madame X by Gioia Diliberto. Albany Museum of Art Executive Director Paula Williams will lead the discussion.
Diliberto's novel imagines the story of Virginie Gautreau, subject of the painting Madame X by John Singer Sargent. In writing it, Diliberto draws upon the few historical facts about Gautreau, a New Orleans native who left Civil War America for France, where she married a French banker. Sargent painted the young socialite, known for her beauty and rumored promiscuity. His work Madame X was seen as sexually suggestive, creating a scandal when it was shown at the Paris Salon of 1884. Gautreau was said to have been humiliated by the event. Sargent soon left Paris to establish himself in Britain and America.
"There's plenty of time to get a copy and read it before the club meeting," Annie Vanoteghem, director of Education and Public Programming for the AMA, said. "It's an informal discussion, there's no cost, and you don't have to attend every meeting to be a club member."
RSVPs may be made by emailing bookclub@albanymuseum.com or by calling 229.439.8400.
Meeting every other month will give club members, who are expected to obtain their own copies of the books, plenty of time to read the selections scheduled for discussion, she said. Club members are asked to RSVP by noon on the meeting date so that the meeting space can be prepared.
Discussion leaders have been scheduled for the first three club meetings. Upcoming dates and selections are:
n July 15: Girl with a Pearl Earring, by Tracey Chevalier. Discussion leader is K.K. Snyder;
n Sept 17: The Picture of Dorian Gray, by Oscar Wilde. Discussion leader is Candice Franklin;
n Nov 19: The Miniaturist, by Jessie Burton;
n Jan 21: An Artist of the Floating World, by Kazuo Ishiguro;
n March 17: I, Juan de Pareja, by Elizabeth Borton de Trevino.
"We hope those participating will feel free to make suggestions for future 'reads' throughout the year," Vanoteghem said.
CURRENT AMA EXHIBITIONS
n Memory and Meaning, works by Masud Olufani, continues in the Haley Gallery through June 15, 2019;
n Undercurrents, works by Jerushia Graham, continues in the East Gallery through June 15, 2019;
n Ghost Yonder Moonscape, works by Zipporah Thompson, continues in the Haley Gallery through June 15, 2019.


Junk it Now! Prices | Senior + Veterans Discounts | Junk it Now!
Since we recycle as much as possible, we can pass on the disposal savings to you!
* If you have just one item you need removed, call for pricing.
* Due to disposal costs beyond our control, all box springs, mattresses, A/C's, refrigerators, computers, TV's, tires, and sleep-sofas (mattresses) will have a separate removal fee. Please call for those prices.
We offer a 10% discount to seniors and veterans.
Please call us now to book your appointment!
Click Here to view full website.
Junk it Now! us 2012-2018 © All Rights Reserved We don"t sell your personal information to third parties.


Each of the lawyers at Davis & Mendelson are parents, as well as lawyers. Our attorneys accordingly understand that family law matters frequently take an emotional toll on children. Consistent with the Children's Bill of Rights, our goal is to always, whatever the issue may be, protect the best interest of the children involved in a family law matter. Accordingly, we pride ourselves on being "kid-centered"; the judges we appear before and our clients accordingly appreciate how, whatever the issue may be, we always consider the impact upon our client and, just as importantly, our client's children.
Our South Jersey law firm, Davis & Mendelson, LLC, assists clients with a wide range of divorce and family law matters. We also use our experience and knowledge in Camden, Burlington and Gloucester counties as volunteers on the Matrimonial Early Settlement Panel. We volunteer at the Rutgers University-Camden domestic violence pro bono project. Attorney Mendelson is an economic mediator for Burlington County. Attorney Mendelson has also served as a Master, along with judges throughout Camden, Burlington and Gloucester counties, with the Thomas S. Forkin American Law Inn of Court.
Our law firm has developed a focus on high-asset divorces. We are able to handle the complex issues that arise during the equitable distribution of property. We work with business valuation specialists, real estate appraisers and other experts to arrive at a just property settlement.
We also work with child psychologists, educational specialists and others who add valuable insight to custody and support determinations. All our experts and specialists are well known to us; we have been working with them for many years as we strive to arrive at fair arrangements for all involved.
We believe that collaborative divorce is less damaging to the divorcing parties and their children than traditional litigation. Collaborative divorce involves the couple and their attorneys working together to identify priorities, interests and goals. While this approach is not for everyone, it can result in a far better outcome for many families. It can also be less expensive than litigation, as the cost of experts and specialists can be shared.
We use whatever approach is best suited to your specific situation and what is best for your children. To learn more about our philosophy of practice in divorce or other family law matters, contact our Voorhees law firm today. Either fill out our form online or call our office directly.
Couples planning a wedding may also wish to consider entering into a prenuptial agreement. Prenuptial agreements are particularly appropriate when either the bride or groom has been married before, has children from a prior relationship and/or has acquired significant assets prior to the marriage. The prenuptial agreement is accordingly a contract between the marrying couple defining their rights in the event of a divorce.
The prenuptial agreement must be entered into prior to the marriage, accurately disclose each parties holdings, and be entered into without fraud, coercion, duress and/or other circumstances which would call into question the voluntariness of the agreement. It is accordingly important for couples who are considering a prenuptial agreement to plan adequately in advance so that they are not reviewing and/or signing the proposed prenuptial agreement at the last minute, without the opportunity to consult with counsel and/or to otherwise investigate the disclosures contained within the prenuptial agreement.
Couples considering prenuptial agreements should accordingly comprise inventories of their respective property holdings, discuss their intentions with one another and retain attorneys to represent them as early as possible. While there is no bright line test as to how much time should pass between the entry of the prenuptial agreement and actual wedding ceremony, the couple should ideally complete the negotiations and sign the prenuptial agreement at or about the same time the couple begins making wedding plans; the comprehensive prenuptial agreement, including all required disclosures, should be reviewed by two attorneys and signed by both parties prior to wedding invitations being sent.
Couples should also recognize that a prenuptial agreement cannot extinguish either party's obligation to support children born of the marriage; provisions within a prenuptial agreement purporting to limit either party's obligation to pay child support to children born of the marriage will not be enforced. It is equally important that each party have their own independent attorney review the proposed prenuptial agreement; the enforceability of the prenuptial agreement can be called into question if either party was not afforded sufficient time and opportunity to review the prenuptial agreement and consult with independent counsel.
Contact an Experienced Camden County Family Law Attorney Today!
We help families get through divorce, child custody battles, alimony disputes and more through mediation. Contact us today to learn how we can help you. Fill out the online form or call us directly at 856-627-0100. We are here for you.


Wood crafting. Dccgglx6684. Type 1: Full length:Type 7: Shoe cleaning kit. Suitable season: Head vacuum. For xiaomi robotic vacuum cleaner mi robot. Shoes clean tools. Cleaning crystal. 16x6x4cm  sko. Zhejiang, china (mainland). Women's winter snow boots. Quantity: Doogalkai. As photo. Wholesale shoe wood. Wool shoeshine gloves.
Feature 1: Inner dia 32mm universal vacuum cleaner spare parts. A1001. Faucet laundry. Shoe care tools. Drying boots. Shoes designer. Clamp boot. S1060. Moonbiffy. Shoe brush. Wholesale appliances kitchen. Winter, spring, autumn. Shoe quick. Sa7819.